TG Therapeutics, Inc.
TG Therapeutics, Inc. (TGTX) Revenue
Annual & quarterly revenue history · segment & region breakdown
TGTX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsTG Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.70B, an increase of 87.32% year-over-year from $0.62B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.62B | +$0.29B | +87.32% |
| 2024-12-31 | $0.33B | +$0.10B | +40.80% |
| 2023-12-31 | $0.23B | +$0.23B | +8290.02% |
| 2022-12-31 | $0.00B | -$0.00B | -58.36% |
| 2021-12-31 | $0.01B | +$0.01B | +4300.66% |
| 2020-12-31 | $0.00B | +$0.00B | +0.00% |
| 2019-12-31 | $0.00B | +$0.00B | +0.00% |
| 2018-12-31 | $0.00B | -$0.00B | -0.25% |
| 2017-12-31 | $0.00B | +$0.00B | +0.00% |
| 2016-12-31 | $0.00B | +$0.00B | +0.00% |
Compare revenue vs peers
BiotechnologyCompare TGTX revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income TG Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
TG Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from TG Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
TGTX revenue · 4 questionsTGTX's trailing twelve-month (TTM) revenue is $0.70B. That is an increase of 87.32% year-over-year from $0.62B in FY2025.
▸ Source: FMP · TG Therapeutics, Inc. SEC filings · GAAP · TG Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026